These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 29855615)

  • 1. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.
    Stamm H; Klingler F; Grossjohann EM; Muschhammer J; Vettorazzi E; Heuser M; Mock U; Thol F; Vohwinkel G; Latuske E; Bokemeyer C; Kischel R; Dos Santos C; Stienen S; Friedrich M; Lutteropp M; Nagorsen D; Wellbrock J; Fiedler W
    Oncogene; 2018 Sep; 37(39):5269-5280. PubMed ID: 29855615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
    Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
    Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia.
    Hattori N; Kawaguchi Y; Sasaki Y; Shimada S; Murai S; Abe M; Baba Y; Watanuki M; Fujiwara S; Arai N; Kabasawa N; Tsukamoto H; Uto Y; Yanagisawa K; Saito B; Harada H; Nakamaki T
    Biol Blood Marrow Transplant; 2019 May; 25(5):861-867. PubMed ID: 30639819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways.
    Yang J; Wang L; Byrnes JR; Kirkemo LL; Driks H; Belair CD; Aguilar OA; Lanier LL; Wells JA; Fong L; Blelloch R
    Cancer Immunol Res; 2024 May; 12(5):575-591. PubMed ID: 38588410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy.
    Murakami K; Ganguly S
    Front Immunol; 2024; 15():1441730. PubMed ID: 39156900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer.
    Stamm H; Oliveira-Ferrer L; Grossjohann EM; Muschhammer J; Thaden V; Brauneck F; Kischel R; Müller V; Bokemeyer C; Fiedler W; Wellbrock J
    Oncoimmunology; 2019; 8(12):e1674605. PubMed ID: 31741778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma.
    Lozano E; Mena MP; Díaz T; Martin-Antonio B; León S; Rodríguez-Lobato LG; Oliver-Caldés A; Cibeira MT; Bladé J; Prat A; Rosiñol L; Fernández de Larrea C
    Clin Cancer Res; 2020 Sep; 26(17):4688-4698. PubMed ID: 32513837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.
    Stanietsky N; Simic H; Arapovic J; Toporik A; Levy O; Novik A; Levine Z; Beiman M; Dassa L; Achdout H; Stern-Ginossar N; Tsukerman P; Jonjic S; Mandelboim O
    Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17858-63. PubMed ID: 19815499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased frequency of TIGIT
    Brauneck F; Haag F; Woost R; Wildner N; Tolosa E; Rissiek A; Vohwinkel G; Wellbrock J; Bokemeyer C; Schulze Zur Wiesch J; Ackermann C; Fiedler W
    Oncoimmunology; 2021 Jun; 10(1):1930391. PubMed ID: 34211801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
    Krupka C; Kufer P; Kischel R; Zugmaier G; Lichtenegger FS; Köhnke T; Vick B; Jeremias I; Metzeler KH; Altmann T; Schneider S; Fiegl M; Spiekermann K; Bauerle PA; Hiddemann W; Riethmüller G; Subklewe M
    Leukemia; 2016 Feb; 30(2):484-91. PubMed ID: 26239198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell RNA sequencing highlights the role of PVR/PVRL2 in the immunosuppressive tumour microenvironment in hepatocellular carcinoma.
    Li A; Ji B; Yang Y; Ye B; Zhu Q; Hu X; Liu Y; Zhou P; Liu J; Gao R; Zhou Q; Kang B; Jiang Y
    Front Immunol; 2023; 14():1164448. PubMed ID: 37383234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth
    Zhou XM; Li WQ; Wu YH; Han L; Cao XG; Yang XM; Wang HF; Zhao WS; Zhai WJ; Qi YM; Gao YF
    Front Immunol; 2018; 9():2821. PubMed ID: 30555485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis.
    Liu G; Zhang Q; Yang J; Li X; Xian L; Li W; Lin T; Cheng J; Lin Q; Xu X; Li Q; Lin Y; Zhou M; Shen E
    Cancer Immunol Immunother; 2022 Feb; 71(2):277-287. PubMed ID: 34129052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer.
    Stamm H; Wellbrock J; Fiedler W
    Mamm Genome; 2018 Dec; 29(11-12):694-702. PubMed ID: 30132062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIGIT blockade repolarizes AML-associated TIGIT
    Brauneck F; Fischer B; Witt M; Muschhammer J; Oelrich J; da Costa Avelar PH; Tsoka S; Bullinger L; Seubert E; Smit DJ; Bokemeyer C; Ackermann C; Wellbrock J; Haag F; Fiedler W
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering.
    Stengel KF; Harden-Bowles K; Yu X; Rouge L; Yin J; Comps-Agrar L; Wiesmann C; Bazan JF; Eaton DL; Grogan JL
    Proc Natl Acad Sci U S A; 2012 Apr; 109(14):5399-404. PubMed ID: 22421438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.
    Laszlo GS; Gudgeon CJ; Harrington KH; Walter RB
    Blood Cancer J; 2015 Aug; 5(8):e340. PubMed ID: 26295610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
    Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.